NASDAQ: CRSP

CRISPR Therapeutics (CRSP) Stock Analysis & Forecast

Nov 13 close

$42.24−0.38 (−0.9%)

Gekko Brief

AI summaryNov 9 close

CRISPR Therapeutics presented positive Phase 1b data for CTX310, its gene editing therapy, showing reductions in ANGPTL3 and triglycerides in patients with severe hypertriglyceridemia at the American Heart Association Scientific Sessions 2026. The company also updated on zugo-cel, its gene-edited CAR-T therapy, for refractory rheumatologic autoimmune diseases, citing positive Phase 1 responses in systemic sclerosis (83% at Month 3) and idiopathic inflammatory myopathy (100% improved). Alongside this clinical news, analysts have trimmed near-term revenue forecasts for 2027 to US$133m while raising loss per share estimates to US$3.57, following a recent quarterly report that missed revenue expectations by 24% and showed a 15% larger loss per share than anticipated.

CRSP closed at $50.04, down 0.1%, sitting between its 50-day average of $53.12 and 200-day average of $52.73. The stock's one-month return stands at -6.3%, with six-month and one-year returns of -7.4% and -11.6%. The GekkoIndex reads 60.2, placing it in the Accumulation zone, and the current price sits 18.9% below Gekko Fair Value of $61.70.

The next earnings date is 11 February 2027, 93 days out, placing it beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears within the respective 90-day and 30-day windows, though recent filings include a Form 144 and a Form 4 from the Chief Technical Officer, along with a proposed officer sale of 79,393 shares. Seasonality over five years shows an average 20-trading-day return of 1.7%, with gains in 3 of those years. Analyst sentiment includes 8 buy and 6 hold ratings among 14 firms, with a consensus target of $74.33.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

CRISPR Therapeutics price vs fair value

$64.26$42.24Nov ’25May ’26Nov ’26
Close $42.24200-day averageGekko Fair Value $64.26

CRISPR Therapeutics quick facts

Market cap
$4.10B
P/E ratio
—
Forward P/E
23.4
EPS, TTM
−$4.73
Revenue, TTM
$25.17M
Profit margin
0%
Dividend yield
—
Beta
1.90
Volume
1.87M avg 1.60M
1-year return
−19.1%
Typical daily move
±6.8%
Typical 20-day move
±10.3%
50-day average
$52.09
200-day average
$52.53
Next earnings
Feb 11 after close
Shares outstanding
97.00M
52-week range
$41.75$63.45

CRISPR Therapeutics swing-trade checklist

CRISPR Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive0 mixed2 headwinds

  • Trendheadwind

    Below 50 and 200-day

    Close $42.24 is below the 50-day ($52.09) and 200-day ($52.53) averages, and the 50-day is below the 200-day.

    See the chart
  • GekkoIndexsupportive

    71.1, Buying

    Reading 71.1 is in the Buying zone.

    See the GekkoIndex
  • Fair valuesupportive

    34.3% below

    Price is 34.3% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −3.6% on average

    From this point in the calendar, the next 20 trading days averaged −3.6% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

CRISPR Therapeutics stock chart and price history

CRISPR Therapeutics closed at $42.24 on Nov 13, 2026, −19.1% over the past year, inside a 52-week range of $41.75 to $63.45.

Close50-day average200-day averageVolume
CRISPR Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$45$50$55$60DecJan 2026FebMarAprMayJunJulAugSepOctNov42.24

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−18.0%
3 months
−22.2%
6 months
−12.7%
1 year
−19.1%
The full CRSP chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CRSP in Gekko

Follow CRISPR Therapeutics through every session

Put CRSP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track CRSP in GekkoFree for 7 days. No credit card required.

About CRISPR Therapeutics

CRISPR Therapeutics works on gene-editing treatments for serious illnesses, built around its CRISPR/Cas9 technology, which allows targeted changes to genetic material. Its research spans blood disorders, cancer, regenerative medicine and rare diseases, and it is best known for CTX001, a gene-edited therapy for transfusion-dependent beta-thalassemia and severe sickle cell disease that works by editing a patient's own stem cells to raise fetal hemoglobin levels.

Beyond CTX001, the company is developing donor-derived CAR-T candidates such as CTX110, CTX120 and CTX130, aimed at different blood cancers and solid tumors, along with VCTX210, a stem cell-based candidate for type 1 diabetes, and additional in vivo editing programs targeting the liver, lungs, muscles and nervous system. It carries out this work partly through partnerships, including ones with Bayer Healthcare, Vertex Pharmaceuticals, ViaCyte, Nkarta and Capsida Biotherapeutics.

CRISPR Therapeutics was founded in 2013 and is headquartered in Zug, Switzerland. Its shares are listed on the NASDAQ under the ticker CRSP.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
crisprtx.com

CRISPR Therapeutics GekkoIndex: the smart money zone

CRISPR Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 71.1, in the Buying zone, up 10.2 points over five sessions.

010071.1Buying

Up 10.2 points over five sessions, from the Accumulation zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying (current zone)37+0.2%+1.1%+3.4%+5.9%
Accumulation272+1.4%+2.3%+3.4%+3.7%
Neutral344−0.9%−1.6%−2.3%−3.4%
Distribution47+0.4%+1.8%0.0%−9.8%
Selling2Too few readings yet

Average CRSP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.

Buying zone: Smart money likely accumulating heavily. About the five zones →

See every daily GekkoIndex reading plotted over the CRSP price, zone by zone.Track CRSP in Gekko

Is CRISPR Therapeutics stock overvalued? Gekko Fair Value

CRISPR Therapeutics trades 34.3% below Gekko Fair Value of $64.26, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what CRISPR Therapeutics shares are worth, recalculated every trading day.

$64.26

Gekko Fair Value, Nov 14, 2026

34.3% Undervalued

At the end of Aug 2026 the price was 24.7% below the estimate.

Gekko Fair ValueShare price, month end
$64$42Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open CRSP in Gekko

CRISPR Therapeutics insider and Congress trading

No open-market insider purchases were filed for CRISPR Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for CRSP in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every CRSP insider filing, plotted on the chart in Gekko.Open CRSP in Gekko

Congress trades last 90 days

No trades in CRSP were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for CRSP, plotted on the chart in Gekko.Open CRSP in Gekko

Buybacks

CRISPR Therapeutics has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$722K
As a share of market cap
0.02%

From company filings.

CRISPR Therapeutics earnings: next date and track record

CRISPR Therapeutics reports on Feb 11, 2027, after the close (88 days away), and beat the EPS estimate in 3 of its last 8 reports.

3 of 8reports beat the EPS estimate
±6.2%average move across the report
5 of 8reports followed by a gain

Share-price move across each report

+9.9%Feb ’25−9.0%May ’25−5.5%Aug ’25+0.2%Nov ’25+9.8%Feb ’26+1.5%May ’26+10.6%Aug ’26−2.8%Nov ’26
ReportedEPSSurpriseRevenueSurpriseMove
Nov 2, 2026−$1.15
est −$1.04
−10.6%$12.67M
est $14.75M
−14.1%−2.8%
Aug 3, 2026−$0.94
est −$1.19
+21.0%$10.18M
est $7.45M
+36.7%+10.6%
May 4, 2026−$1.28
est −$1.23
−4.1%$1.46M
est $6.06M
−76.0%+1.5%
Feb 12, 2026−$1.37
est −$1.17
−17.1%$864K
est $4.72M
−81.7%+9.8%
Nov 10, 2025−$1.17
est −$1.31
+10.7%$889K
est $9.12M
−90.3%+0.2%
Aug 5, 2025−$2.40
est −$1.47
−63.3%$892K
est $6.14M
−85.5%−5.5%
May 6, 2025−$1.58
est −$1.27
−24.4%$865K
est $5.96M
−85.5%−9.0%
Feb 11, 2025−$0.44
est −$1.19
+62.9%$35.00M
est $8.06M
+334.5%+9.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

CRISPR Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for CRISPR Therapeutics is $85.42, +102.2% from the last close, from 14 firms rating the stock in the last 90 days.

$85.42consensus 12-month target, +102.2% from the last close
Low $45High $110
Buy8
Hold6
Sell0

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9Piper SandlerBuy, reiterated$110+160.4%
Nov 9NeedhamBuy, maintained$82+94.1%
Nov 9H.C. WainwrightBuy, reiterated$80+89.4%
Nov 9J.P. MorganBuy, maintained$67+58.6%
Nov 8CitiBuy, maintained$90+113.1%
+3.4%average 20-day move after past Buying readings
−3.6%average move over the next 20 trading days in the last 5 years
±6.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

CRISPR Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, CRISPR Therapeutics averaged −3.6% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−12.3%2021−15.2%2022+11.1%2023−6.6%2024+7.1%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.1%1 of 5
Next 10 trading days+1.8%2 of 5
Next 15 trading days+2.9%2 of 5
Next 20 trading days−3.6%2 of 5
Next 30 trading days−9.3%2 of 5

For scale, CRSP’s typical 20-trading-day move in either direction is about 10.3%.

CRISPR Therapeutics market cap and key statistics

CRISPR Therapeutics’s market cap is $4.10B and revenue of $25.17M over the last twelve months.

Valuation

Market cap
$4.10B
Forward P/E
23.4
EPS, TTM
−$4.73
Gekko Fair Value
$64.26

Trading

Volume
1.87M
Avg volume, 20 days
1.60M
52-week high
$63.45
52-week low
$41.75
Shares outstanding
97.00M

Financials

Revenue, TTM
$25.17M
Profit margin
0%
Return on equity
-25.6%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
1.90
Typical daily move
±6.8%
Typical 20-day move
±10.3%

CRISPR Therapeutics peers

CRISPR Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

CRISPR Therapeutics stock FAQ

What is CRISPR Therapeutics’s market cap?

CRISPR Therapeutics’s market cap is $4.10B at the Nov 13, 2026 close of $42.24, with 97.00M shares outstanding.

What is the CRISPR Therapeutics stock forecast?

The consensus analyst 12-month price target for CRISPR Therapeutics is $85.42, +102.2% from the last close. Of the 14 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is CRISPR Therapeutics stock overvalued or undervalued?

On Gekko’s estimate CRISPR Therapeutics is undervalued: the Nov 13, 2026 close of $42.24 is 34.3% below Gekko Fair Value of $64.26. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does CRISPR Therapeutics report earnings next?

CRISPR Therapeutics is expected to report on Feb 11, 2027, after the market closes (88 days away). Analysts expect earnings of −$1.17 per share on revenue of $11.34M. CRISPR Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 6.2% on average across the report.

What is CRISPR Therapeutics’s 52-week high and low?

CRISPR Therapeutics’s 52-week high is $63.45 and its 52-week low is $41.75; it closed at $42.24 on Nov 13, 2026, −19.1% over the past year. Over the last five years the shares peaked at $91.10 on Feb 22, 2024.

Is CRISPR Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See CRISPR Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.